摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

9,9-dimethyl-5,6,8,9,10,11-hexahydro-12H-azepino[3',4':4,5]pyrrolo[2,1-a]isoquinolin-12-one | 1136691-84-3

中文名称
——
中文别名
——
英文名称
9,9-dimethyl-5,6,8,9,10,11-hexahydro-12H-azepino[3',4':4,5]pyrrolo[2,1-a]isoquinolin-12-one
英文别名
13,13-Dimethyl-10,15-diazatetracyclo[8.8.0.02,7.011,17]octadeca-1(18),2,4,6,11(17)-pentaen-16-one
9,9-dimethyl-5,6,8,9,10,11-hexahydro-12H-azepino[3',4':4,5]pyrrolo[2,1-a]isoquinolin-12-one化学式
CAS
1136691-84-3
化学式
C18H20N2O
mdl
——
分子量
280.37
InChiKey
IEVPERBVWQQXBK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    21
  • 可旋转键数:
    0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.39
  • 拓扑面积:
    34
  • 氢给体数:
    1
  • 氢受体数:
    1

反应信息

  • 作为产物:
    描述:
    9,9-dimethyl-5,8,9,10-tetrahydroindolo[2,1-a]isoquinolin-11(6H)-one oxime 在 四磷十氧化物磷酸 作用下, 反应 3.0h, 以28%的产率得到9,9-dimethyl-5,6,8,9,10,11-hexahydro-12H-azepino[3',4':4,5]pyrrolo[2,1-a]isoquinolin-12-one
    参考文献:
    名称:
    新型azepino [3',4':4,5]吡咯并[2,1 - a ]异喹啉-12-ones的合成及细胞毒活性
    摘要:
    作为潜在的细胞毒性化合物,设计了一系列azepino [3',4':4,5]吡咯并[2,1 - a ]异喹啉-12-酮(3a–f),它们是前导化合物2的构象受限类似物。并以自由基氧化性芳族取代反应为关键步骤进行合成。在5种肿瘤细胞系上测试了化合物3a–f,以确定化合物2的生物学活性的构象要求。结果表明,对化合物2的构象限制(生成衍生物3a - f)并没有明显降低2的细胞毒活性,尽管化合物3d(R = Br)显示出对U-251细胞的良好活性。对这些化合物进行的初步结构-活性关系研究表明,结合至异喹啉部分的卤素非常重要。此外,衍生物3f(R = NO 2)和3b(R = F)对PC-3和K-562细胞具有细胞毒性。然而,azepino [3',4':4,5]吡咯并[2,1- a ]异喹啉酮均未抑制CDK1 / cyclin B,CDK5 / p25或GSK-3的酶活性。
    DOI:
    10.1016/j.bmc.2009.01.056
点击查看最新优质反应信息

文献信息

  • Synthesis and cytotoxic activity of new azepino[3′,4′:4,5]pyrrolo[2,1-a]isoquinolin-12-ones
    作者:Roberto Martínez、Martha Menes Arzate、Ma. Teresa Ramírez-Apan
    DOI:10.1016/j.bmc.2009.01.056
    日期:2009.3
    A series of azepino[3′,4′:4,5]pyrrolo[2,1-a]isoquinolin-12-ones (3a–f), that were conformationally restricted analogs of lead compound 2, were designed as potential cytotoxic compounds and synthesized using a radical oxidative aromatic substitution reaction as the key step. Compounds 3a–f were tested on five tumor cell lines to determine the conformational requirements for biological activity of compound
    作为潜在的细胞毒性化合物,设计了一系列azepino [3',4':4,5]吡咯并[2,1 - a ]异喹啉-12-酮(3a–f),它们是前导化合物2的构象受限类似物。并以自由基氧化性芳族取代反应为关键步骤进行合成。在5种肿瘤细胞系上测试了化合物3a–f,以确定化合物2的生物学活性的构象要求。结果表明,对化合物2的构象限制(生成衍生物3a - f)并没有明显降低2的细胞毒活性,尽管化合物3d(R = Br)显示出对U-251细胞的良好活性。对这些化合物进行的初步结构-活性关系研究表明,结合至异喹啉部分的卤素非常重要。此外,衍生物3f(R = NO 2)和3b(R = F)对PC-3和K-562细胞具有细胞毒性。然而,azepino [3',4':4,5]吡咯并[2,1- a ]异喹啉酮均未抑制CDK1 / cyclin B,CDK5 / p25或GSK-3的酶活性。
查看更多

同类化合物

环戊二烯并[4,5]氮杂卓并[2,1,7-cd]吡咯里嗪 吡咯并[1,2-a]氮杂-5-酮 六氢-1H-吡咯并[1,2-A]氮杂卓-5(6H)-酮 N,N-二甲基-3-(3-甲基-1,2,4,5-四氢氮杂卓并[4,5-b]吲哚-6-基)丙-1-胺 9-氟-1,2,3,4,5,6-六氢氮杂卓并[4,5-b]吲哚 7,8-二氢-5H-吡咯并[1,2-A]氮杂环庚烷-9(6H)-酮 6-叔-丁基3A-乙基八氢吡咯并[2,3-D]氮杂卓-3A,6(2H)-二甲酸基酯 6,7-二氢吡咯并[2,3-c]氮杂卓-4,8(1H,5H)-二酮 5H-吡咯并[1,2-a]氮杂卓-7-醇 5,9:7,11-二亚甲基-5H-吡咯并[1,2-a]吖壬英-3-羧酸,6,7,8,9,10,11-六氢-,甲基酯 4-(2-氨基-1H-咪唑-5-基)-2,3-二溴-6,7-二氢吡咯并[2,3-c]氮杂卓-8(1H)-酮 4-(2-氨基-1H-咪唑-4-基)-2,3-二溴-4,5,6,7-四氢吡咯并[2,3-c]氮杂卓-8(1H)-酮 4-(2-氨基-1,5-二氢-5-氧代-4H-咪唑-4-亚基)-4,5,6,7-四氢-吡咯并[2,3-c]氮杂卓-8(1H)-酮 3-苄基-1,2,3,4,5,6-六氢氮杂卓并[4,5-b]吲哚 3-(3,9-二甲基-1,2,4,5-四氢氮杂卓并[4,5-b]吲哚-6-基)-N,N-二甲基丙烷-1-胺 2H,3H-氧杂环丁烷并[3,2-d]吡咯并[1,2-a]氮杂卓 2-溴-6,7-二氢-1h,5h-吡咯并[2,3-c]氮杂烷-4,8-二酮 2,5-已炔二醇 2,3,4,5-四氢-N,N-二甲基-2-(3,4,5-三甲氧基苯甲酰基)-氮杂卓并(3,4-b)吲哚-10(1H)-丙胺 11-氧杂-3,10-二氮杂三环[7.2.1.03,7]十二碳-1,4,6,9-四烯 1,4,5,6,7,8-六氢吡咯并[3,2-b]氮杂卓 1,2,3,4,5,6-六氢氮杂环庚烷[4,3-B]吲哚盐酸盐 1,2,3,4,5,6-六氢-9-甲基氮杂卓并[4,5-b]吲哚 1,2,3,4,5,6-六氢-6-甲基氮杂革[4,5-b]吲哚盐酸盐 1,2,3,4,5,6-六氢-3-甲基氮杂卓并[4,5-b]吲哚 (1R*,2E,11S*)-2-(cyclohexylmethylene)-1-(phenylsilyl)methyloctahydropyrrolo[1,2-a]azepine (R)-2-(6,7,8,9-tetrahydro-5H-pyrrolo[1,2-a]azepin-9-yl)-acetaldehyde curvulamine (3aR,8aS)-tert-butyl octahydropyrrolo[3,4-d]azepine-2(1H)-carboxylate hydrochloride tert-butyl 6-(2-amino-2-oxoethyl)-1,4,5,6-tetrahydroazepino[4,5-b]indole-3(2H)-carboxylate 3-benzoyl-10-bromo-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole 3-(tert-butyloxycarbonyl)-10-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole 1,2,3,4,5,6-hexahydro-3-dimethylaminoethyl-5-hydroxymethylazepino[4,5-b]indole 1,2,3,4,5,6-hexahydro-3-dimethylaminoethyl-5-hydroxymethyl-6-methylazepino[4,5-b]indole (Z)-2,3,9,9a-tetrahydro-6,6-dimethyl-9-methylene-8-vinyl-1H-pyrrolo[1,2-a]azepin-5(6H)-one 2,3,4,5,6,7-hexahydro-1H-3a,8,13,13b-tetraazabenzo[b]cyclopenta[1,2,3-jk]fluorene 2,3,4,5,6,7-hexahydro-1H-3a,8,11,11b-tetraazacyclohepta[1,2,3-jk]fluorene 1-Benzyloxy-2-methoxy-7,8,9,10-tetrahydro-6H-azepino<1,2-a>indole-11-carbaldehyde 3-benzoyl-10-(2-propoxyphenyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole 2-phenyl-2,4,5,6-tetrahydro-1H-6-azabenzo[a]cyclohepta[cd]azulen-1-one 2-carbetoxy-3-(N,N-dimethyl)aminomethyleneamino-8-oxo-8H-4,5,6,7-tetrahydropyrrolo<2,3-c>azepine 3-benzoyl-10-[2-(trifluoromethyl)phenyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole 3-benzoyl-10-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole 6-[2-(4-fluorophenyl)ethyl]-3,4,5,6-tetrahydroazepino[4,3-b]indol-1(2H)-one 5-(2-hydroxy-3-morpholin-4-yl-propyl)-3-methyl-4-oxo-1,4,5,6,7,8-hexahydro-pyrrolo[3,2-c]azepine-2-carbaldehyde 6-(2-phenylethyl)-3,4,5,6-tetrahydroazepino[4,3-b]indol-1(2H)-one 11-(tert-butyldimethylsilyloxy)-1-trimethylsilyl-3a,4,11,12-tetrahydro-3H-cyclopenta[5,6]azepine[1,2-a]indole-2-one tert-butyl 8,9-dichloro-6-[2-(2,3-dimethylanilino)-2-oxoethyl]-1,4,5,6-tetrahydroazepino[4,5-b]indole-3(2H)-carboxylate tert-butyl 9,10-dichloro-6-[2-(2,3-dimethylanilino)-2-oxoethyl]-1,4,5,6-tetrahydroazepino[4,5-b]indole-3(2H)-carboxylate tert-butyl (1R,4S)-1-(benzylcarbamoyl)-3-oxo-2-((S)-1-phenylethyl)-1,2,3,4,5,10-hexahydroazepino[3,4-b]indol-4-ylcarbamate